Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.

Udyavar AR, Wooten DJ, Hoeksema M, Bansal M, Califano A, Estrada L, Schnell S, Irish JM, Massion PP, Quaranta V.

Cancer Res. 2017 Mar 1;77(5):1063-1074. doi: 10.1158/0008-5472.CAN-16-1467. Epub 2016 Dec 8. Erratum in: Cancer Res. 2019 Mar 1;79(5):1014.

2.

Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.

Krohn A, Ahrens T, Yalcin A, Plönes T, Wehrle J, Taromi S, Wollner S, Follo M, Brabletz T, Mani SA, Claus R, Hackanson B, Burger M.

PLoS One. 2014 Jun 24;9(6):e100249. doi: 10.1371/journal.pone.0100249. eCollection 2014.

3.

YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.

Horie M, Saito A, Ohshima M, Suzuki HI, Nagase T.

Cancer Sci. 2016 Dec;107(12):1755-1766. doi: 10.1111/cas.13078. Epub 2016 Nov 25.

4.

Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.

Ito T, Kudoh S, Ichimura T, Fujino K, Hassan WA, Udaka N.

Hum Cell. 2017 Jan;30(1):1-10. doi: 10.1007/s13577-016-0149-3. Epub 2016 Oct 26. Review.

PMID:
27785690
5.

Irradiation Decreases the Neuroendocrine Biomarker Pro-Opiomelanocortin in Small Cell Lung Cancer Cells In Vitro and In Vivo.

Meredith SL, Bryant JL, Babur M, Riddell PW, Behrouzi R, Williams KJ, White A.

PLoS One. 2016 Feb 5;11(2):e0148404. doi: 10.1371/journal.pone.0148404. eCollection 2016.

6.

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.

Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V.

BMC Syst Biol. 2013;7 Suppl 5:S1. doi: 10.1186/1752-0509-7-S5-S1. Epub 2013 Dec 9.

7.

Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.

Takakuwa O, Maeno K, Kunii E, Ozasa H, Hijikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, Niimi A.

Lung Cancer. 2013 Aug;81(2):174-9. doi: 10.1016/j.lungcan.2013.04.022. Epub 2013 May 23.

PMID:
23706418
8.

The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.

Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP.

Oncogene. 2013 Jul 25;32(30):3559-68. doi: 10.1038/onc.2012.362. Epub 2012 Aug 20.

9.

ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.

Shukla V, Rao M, Zhang H, Beers J, Wangsa D, Wangsa D, Buishand FO, Wang Y, Yu Z, Stevenson HS, Reardon ES, McLoughlin KC, Kaufman AS, Payabyab EC, Hong JA, Zhang M, Davis S, Edelman D, Chen G, Miettinen MM, Restifo NP, Ried T, Meltzer PA, Schrump DS.

Cancer Res. 2017 Nov 15;77(22):6267-6281. doi: 10.1158/0008-5472.CAN-17-0570. Epub 2017 Sep 21.

10.

Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion.

Hahn N, Heiden M, Seitz R, Salge-Bartels U.

J Cancer Res Clin Oncol. 2012 Apr;138(4):695-703. doi: 10.1007/s00432-011-1139-1. Epub 2012 Jan 12.

PMID:
22237453
11.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA.

Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.

12.

Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.

Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R.

Cell Adh Migr. 2016 Jul 3;10(4):360-7. doi: 10.1080/19336918.2016.1155019. Epub 2016 Feb 26.

13.

Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation.

Ishii J, Sato H, Yazawa T, Shishido-Hara Y, Hiramatsu C, Nakatani Y, Kamma H.

Pathol Int. 2014 Sep;64(9):415-22. doi: 10.1111/pin.12198.

PMID:
25243889
14.

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.

Huang YH, Klingbeil O, He XY, Wu XS, Arun G, Lu B, Somerville TDD, Milazzo JP, Wilkinson JE, Demerdash OE, Spector DL, Egeblad M, Shi J, Vakoc CR.

Genes Dev. 2018 Jul 1;32(13-14):915-928. doi: 10.1101/gad.314815.118. Epub 2018 Jun 26.

15.

Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.

Fujino K, Motooka Y, Hassan WA, Ali Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi H, Kubota I, Wakimoto J, Suzuki M, Ito T.

Am J Pathol. 2015 Dec;185(12):3164-77. doi: 10.1016/j.ajpath.2015.08.018. Epub 2015 Oct 23.

PMID:
26482608
16.

System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.

Donakonda S, Sinha S, Dighe SN, Rao MRS.

Mol Biosyst. 2017 Jul 25;13(8):1481-1494. doi: 10.1039/c6mb00851h.

PMID:
28742165
17.

Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma.

Wael H, Yoshida R, Kudoh S, Hasegawa K, Niimori-Kita K, Ito T.

Lung Cancer. 2014 Aug;85(2):131-40. doi: 10.1016/j.lungcan.2014.05.001. Epub 2014 May 13.

PMID:
24888228
18.

Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.

Pujol JL, Simony J, Laurent JC, Richer G, Mary H, Bousquet J, Godard P, Michel FB.

Cancer Res. 1989 May 15;49(10):2797-802.

19.

Evaluation of role of Notch3 signaling pathway in human lung cancer cells.

Hassan WA, Yoshida R, Kudoh S, Motooka Y, Ito T.

J Cancer Res Clin Oncol. 2016 May;142(5):981-93. doi: 10.1007/s00432-016-2117-4. Epub 2016 Feb 2.

PMID:
26838758
20.

Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer.

Yazawa T, Sato H, Shimoyamada H, Okudela K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, Ishii J, Miyata C, Sakaeda M, Goto K, Kashiwagi K, Masuda M, Takahashi T, Kitamura H.

Am J Pathol. 2009 Sep;175(3):976-87. doi: 10.2353/ajpath.2009.081004. Epub 2009 Aug 13.

Supplemental Content

Support Center